Lantern Pharma (NASDAQ: LTRN) announced the launch of ZetaOmics, the computational biology module of its multi-agentic AI co-scientist platform withZeta.ai. The new platform introduces an autonomous “Computational Biologist” agent designed to perform end-to-end bioinformatics and multi-omic analysis across cancer types. Initially available through an early-access program for select academic, industry and company collaborators, ZetaOmics aims to automate complex research workflows while embedding domain-specific intelligence to improve analytical rigor and reproducibility.
According to the company, ZetaOmics combines 14 specialized tools that can autonomously design, execute and validate biological analyses, detect potential flaws in experimental design and generate publication-quality results with a complete audit trail. This capability is expected to significantly reduce the time and effort required for researchers to conduct multi-omic studies, which often involve large datasets from genomics, transcriptomics, proteomics and other omics fields.
The launch of ZetaOmics expands withZeta.ai’s commercial opportunity beyond rare cancers. Lantern said the platform targets academic medical centers, biotechnology and pharmaceutical companies, cancer centers and contract research organizations through subscription-based offerings and strategic collaborations. This move positions Lantern to generate a new revenue stream from its AI platform, which was previously focused on internal drug development.
Lantern Pharma is a clinical-stage precision oncology company leveraging AI and its proprietary RADR platform to transform cancer therapy development. Its clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
The ZetaOmics platform is part of withZeta.ai, Lantern’s multi-agentic AI co-scientist platform that is now commercially available as a subscription-based research platform. This represents a strategic shift for the company, allowing it to monetize its AI capabilities beyond its own pipeline. By offering ZetaOmics to the broader biomedical community, Lantern aims to accelerate cancer research while generating recurring revenue.
The implications of this announcement are significant for the field of precision oncology. ZetaOmics could democratize access to advanced bioinformatics tools, enabling smaller research institutions and companies to conduct sophisticated multi-omic analyses without needing extensive in-house computational expertise. The platform’s ability to autonomously detect flaws in experimental design and maintain a complete audit trail may also enhance the reproducibility of research findings, a long-standing challenge in biomedical science.
For more information, visit the full press release at https://ibn.fm/9sIIl.
